Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals, Inc.verified

RYTM

Price:

$49.57

Market Cap:

$3.02B

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesit...[Read more]

Industry

Biotechnology

IPO Date

2017-10-09

Stock Exchange

NASDAQ

Ticker

RYTM

The PE Ratio as of July 2024 (TTM) for Rhythm Pharmaceuticals, Inc. (RYTM) is -10.71

According to Rhythm Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -10.71. This represents a change of 28.21% compared to the average of -8.35 of the last 4 quarters.

Rhythm Pharmaceuticals, Inc. (RYTM) Historical PE Ratio (quarterly & annually)

How has RYTM PE Ratio performed in the past?

The mean historical PE Ratio of Rhythm Pharmaceuticals, Inc. over the last ten years is -20.40. The current -10.71 PE Ratio has changed 5.15% with respect to the historical average. Over the past ten years (40 quarters), RYTM's PE Ratio was at its highest in in the March 2021 quarter at 5.79. The PE Ratio was at its lowest in in the June 2017 quarter at -28.75.

Quarterly (TTM)
Annual

Average

-20.40

Median

-11.35

Minimum

-70.37

Maximum

-6.21

Rhythm Pharmaceuticals, Inc. (RYTM) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Rhythm Pharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 73.17%

Maximum Annual PE Ratio = -6.21

Minimum Annual Increase = -57.20%

Minimum Annual PE Ratio = -70.37

Quarterly (TTM)
Annual
YearPE RatioChange
2023-14.3673.17%
2022-8.2913.89%
2021-7.28-27.47%
2020-10.0461.55%
2019-6.21-44.80%
2018-11.25-1.62%
2017-11.44-41.04%
2016-19.40-57.20%
2015-45.33-35.59%
2013-70.37-15.40%

Rhythm Pharmaceuticals, Inc. (RYTM) Average PE Ratio

How has RYTM PE Ratio performed in the past?

The current PE Ratio of Rhythm Pharmaceuticals, Inc. (RYTM) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages

3-year avg

-9.97

5-year avg

-9.23

10-year avg

-20.40

Rhythm Pharmaceuticals, Inc. (RYTM) PE Ratio vs. Peers

How is RYTM’s PE Ratio compared to its peers?

Rhythm Pharmaceuticals, Inc.’s PE Ratio is greater than Revolution Medicines, Inc. (-15.69), less than Akero Therapeutics, Inc. (-8.85), greater than Avidity Biosciences, Inc. (-17.21), less than Protagonist Therapeutics, Inc. (13.35), less than Stoke Therapeutics, Inc. (-5.79), less than uniQure N.V. (-1.26), less than Rocket Pharmaceuticals, Inc. (-8.56), less than Solid Biosciences Inc. (-3.48), less than MeiraGTx Holdings plc (-3.82), greater than Nuvalent, Inc. (-34.81), less than Ventyx Biosciences, Inc. (-0.82), greater than Arcellx, Inc. (-65.30), less than Cullinan Oncology, Inc. (-5.94), less than Kiniksa Pharmaceuticals, Ltd. (173.36), less than Pliant Therapeutics, Inc. (-4.36), less than Syndax Pharmaceuticals, Inc. (-8.17), less than Viridian Therapeutics, Inc. (-4.05), less than Inozyme Pharma, Inc. (-4.27), less than Relay Therapeutics, Inc. (-3.42), less than Black Diamond Therapeutics, Inc. (-3.73), less than Arvinas, Inc. (-5.76),

Build a custom stock screener for Rhythm Pharmaceuticals, Inc. (RYTM) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Rhythm Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Rhythm Pharmaceuticals, Inc. (RYTM) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Rhythm Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Rhythm Pharmaceuticals, Inc.'s PE Ratio?

How is the PE Ratio calculated for Rhythm Pharmaceuticals, Inc. (RYTM)?

What is the highest PE Ratio for Rhythm Pharmaceuticals, Inc. (RYTM)?

What is the 3-year average PE Ratio for Rhythm Pharmaceuticals, Inc. (RYTM)?

What is the 5-year average PE Ratio for Rhythm Pharmaceuticals, Inc. (RYTM)?

How does the current PE Ratio for Rhythm Pharmaceuticals, Inc. (RYTM) compare to its historical average?